Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SGN-40: Phase Ib started

SGEN began an open-label, dose-escalation, U.S. Phase Ib trial in up

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE